Bone Mineral Density Changes in Patients With Prostate Cancer During the First 2 Years of Androgen Suppression

Journal of Urology

Volumn 175, Issue 5, 2006, Pages 1679-1683

  Morote, Juan ^a   Orsola, Anna ^a   Abascal, Jose M ^a   Planas, Jacques ^a   Trilla, Enrique ^a   Raventos, Carles X ^a   Cecchini, Lluis ^a   Encabo, Gloria ^a   Reventos, Jaume ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

androgens; osteoporosis; prostatic neoplasms

Indexed keywords

ANDROGEN; GONADORELIN AGONIST; TESTOSTERONE;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; BONE DISEASE; BONE MASS; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; GLEASON SCORE; HIP; HORMONE INHIBITION; HUMAN; LONG TERM CARE; LUMBAR SPINE; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BONE DENSITY; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 33645987269     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00999-7     Document Type: Article

References (20)

1. Daniell H.W. Osteoporosis after orchiectomy for prostate cancer. J Urol 157 (1997) 439
2. Morote J., Martinez E., Trilla E., Esquena S., Abascal J.M., Encabo G., et al. Osteoporosis during continuous androgen deprivation influence of the modality and length of treatment. Eur Urol 44 (2003) 661
3. Oefelein M.G., Ricchiuti V., Conrad W., and Resnick M.I. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168 (2002) 1005
4. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis (report of WHO Study Group) (1994), World Health Organization, New York
5. Pouilles J.M., Tremollieres F., and Ribot C. Variability of vertebral and femoral postmenopausal bone loss a longitudinal study. Osteoporos Int 6 (1996) 320
6. Collinson M.P., Tyrrel C.J., and Hutton C. Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate. Calcif Tissue Int 54 (1994) 327
7. Hussain S.A., Weston R., Stephenson R.N., George E., and Parr N.J. Immediate dual energy X-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int 92 (2003) 690
8. Kiratli B.J., Srinivas S., Perkash I., and Terris M.K. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 57 (2001) 127
9. McGrath S.A., and Diamond T. Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. J Urol 154 (1995) 535
10. Stepan J.J., Lachman M., Zverina J., Pacovsky V., and Baylink D.J. Castrated men exhibit bone loss effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocrinol Metab 69 (1989) 523
11. Wei J.T., Gross M., Jaffe C.A., Gravlin K., Lahaie M., Faerber G.J., et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 54 (1999) 607
12. Berruti A., Dogliotti L., Terrone C., Cerutti S., Isaia G., Tarabuzzi R., et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167 (2002) 2361
13. Daniell H.W., Dunn S.R., Ferguson D.W., Lomas G., Niazi Z., and Stratte P.T. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163 (2000) 181
14. Maillefert J.F., Sibilia J., Michel F., Saussine C., Javier R.M., and Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 161 (1999) 1219
15. Mittan D., Lee S., Miller E., Perez R.C., Basler J.W., and Bruder J.M. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87 (2002) 3656
16. Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., and Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169 (2003) 2008
17. Smith M.R., McGovern F.J., Zietman A.L., Fallon M.A., Hayden D.L., Schoenfeld D.A., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 (2001) 948
18. Smith M.R., McGovern F.J., Fallon M.A., Schoenfeld D., Kantoff P.W., and Finkelstein J.S. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 91 (2001) 2238
19. Shahinian V.B., Kuo Y.F., Freeman J.L., and Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154
20. Morote J., Trilla E., Esquena S., Abascal J.M., Segura R.M., Catalan R., et al. Analysis of bone alkaline phosphatase as a marker for the diagnosis of osteoporosis in men under androgen ablation. Int J Biol Markers 18 (2003) 290